• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Summary: Mediobanca SpA Mar 12

  • ID: 2091889
  • March 2012
  • Standard & Poors

Strong domestic franchise sustained by successful organic growth. Adequate capitalization. Satisfactory asset quality ratios. Funding sources more concentrated than peers'. Large equity portfolio that exposes the bank to stock market fluctuations. High asset concentration in Italy. The negative outlook reflects the possibility that Standard & Poor's Ratings Services could lower the ratings on Italy-based Mediobanca SpA if we lower our ratings on the Republic of Italy or we see further weakening in the domestic economy and the banking industry. We would also consider lowering the ratings if we considered that our forecast risk-adjusted capital (RAC) ratio for the bank and funding access were likely to weaken substantially. Under our base-line scenario, we anticipate that Mediobanca's RAC before diversification adjustments should...

Companies mentioned in this report are:
- Mediobanca SpA

Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users READ MORE >

Note: Product cover images may vary from those shown

- Mediobanca SpA

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Fluidigm Corporation Apple, Inc. CEVA Santé Animale Abbott Laboratories Ltd. Merck Group Allergan Inc. Pfizer, Inc.